The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient.

Lateral flow devices, methods and kits for performing lateral flow western blot assays are provided.

Methods are disclosed for producing populations of cardiomyocytes from pluripotent stem cells. Populations may be enriched for either atrial or ventricular cardiomyocytes and the resulting ventricular population may be essentially free of pacemaker cells. The method includes incubating pluripotent stem cells in a suitable medium with a BMP component, and an activin component, the amounts of activin may be varied to enrich for either atrial or ventricular cardiomyocytes. The enriched populations, as well as methods of using the same to treat patients in need of cardiac repair are disclosed.

A method of identifying cancer stem cell markers in a human primary tumor is disclosed. The method comprises: (a) in vivo passaging the primary tumor; and (b) comparing a level of at least one antigen in a first population of passaged tumor cells of the primary tumor with a second population of tumor cells of the primary tumor, wherein an increase in the amount of the antigen in the first population of tumor cells as compared to the amount of the antigen in the second population of tumor cells is indicative of a cancer stem cell marker in the human primary tumor.

The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

A detection system for determining pyruvate dehydrogenase (PDH) levels in a bodily sample includes at least one reaction solution for generating NAD.sup.+ upon combination with PDH in the bodily sample, the reaction solution including pyruvate and NADH and a biosensor for determining the level of generated NAD.sup.+.

The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient.

The present disclosure relates to a new process for construction of controlled structures on the surface of modified digital barcoded magnetic beads (BMB) with higher capacity, higher fluorescence intensity, wider dynamic range, and improved sensitivity in clinical applications.

A biosensor for detecting triglycerides. The biosensor includes screen printed carbon electrodes (SPCEs), immobilised lipase and one or more other immobilised enzyme(s).

Disclosed herein are method and compounds useful in the analysis, diagnosis, and treatment of high grade serous ovarian carcinoma (HGSOC). Also disclosed are methods, compounds, and compositions useful in regulating Chromobox 2 (CBX2) expression and therapies for stemness, anoikis escape, HGSOC dissemination, and HGSOC chemoresistance. Applicants have identified CBX2 expression as being significantly elevated in HGSOC cells and tissues compared to benign counterparts. Also disclosed is elevated CBX2 expression in HGSOC cell lines, as well as elevated CBX2 expression in cells that are forced to grown in suspension. CBX2 expression can be used to identify subjects for treatment with therapies specifically directed to cancers characterized by CBX2 upregulation.